Annexon (ANNX) Non Operating Income (2021 - 2026)
Annexon (ANNX) posted quarterly Non Operating Income of $1.9 million for Q1 2026, down 37.32% year-over-year from $3.0 million in Q1 2025, and down 4.55% quarter-over-quarter from $2.0 million in Q4 2025.
Annexon (ANNX) Non Operating Income (2021 - 2026) Analysis & Trends
Annexon's Non Operating Income history runs 6 years deep, the most recent figure standing at $1.9 million for Q1 2026.
- In Q1 2026, Non Operating Income fell 37.32% year-over-year to $1.9 million; the TTM figure through Mar 2026 stood at $8.6 million (down 44.74% YoY), while the FY2025 annual figure was $9.7 million, down 38.78% from the prior year.
- Non Operating Income for Q1 2026 stood at $1.9 million, down from $2.0 million in the prior quarter.
- The five-year high for Non Operating Income was $4.6 million in Q3 2024, with the low at $53000.0 in Q1 2022.
- The 5-year median for Non Operating Income is $2.3 million (2022), against an average of $2.4 million.
- The sharpest annual moves came in 2022 and 2023: Non Operating Income slumped 62.68% in 2022, then soared 4741.51% in 2023.
- Annexon's Non Operating Income stood at $2.3 million in 2022, then decreased by 8.39% to $2.1 million in 2023, then surged by 83.62% to $3.9 million in 2024, then tumbled by 48.52% to $2.0 million in 2025, then decreased by 4.55% to $1.9 million in 2026.
- Business Quant data shows ANNX's Non Operating Income at $1.9 million in Q1 2026, $2.0 million in Q4 2025, and $2.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -139.24 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 12.40 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -51.63 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -53.64 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Annexon | 1.00 Bn | 1.00 Bn | - | 1.88 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.88 Mn |
| Mar 31, 2026 | 1.91 Mn |
| Dec 31, 2025 | 2.00 Mn |
| Sep 30, 2025 | 2.10 Mn |
| Jun 30, 2025 | 2.57 Mn |
| Mar 31, 2025 | 3.05 Mn |
| Dec 31, 2024 | 3.89 Mn |
| Sep 30, 2024 | 4.62 Mn |
| Jun 30, 2024 | 3.97 Mn |
| Mar 31, 2024 | 3.40 Mn |
| Dec 31, 2023 | 2.12 Mn |
| Sep 30, 2023 | 2.30 Mn |
| Jun 30, 2023 | 2.50 Mn |
| Mar 31, 2023 | 2.57 Mn |
| Dec 31, 2022 | 2.31 Mn |
| Sep 30, 2022 | 1.02 Mn |
| Jun 30, 2022 | 272,000.00 |
| Mar 31, 2022 | 53,000.00 |
| Dec 31, 2021 | 87,000.00 |
| Sep 30, 2021 | 82,000.00 |